Page 2 - Alz Res Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields TOKYO, July 29, 2021 /PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, Biogen ) today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 following 18 months of treatment in the open-label extension (OLE) of the Phase 2b proof-of-concept study in subjects with early Alzheimer s disease (AD) (Mild Cognitive Impairment [MCI] due to AD and mild AD) at the Alzheimer s Association International Conference (AAIC) held in Denver, Colo., United States and virtually from July 26 to 30, 2021 (Presentation No.: 57780).

United statesUnited kingdomHaruo naitoCharles weissmannWalter gilbertHeinz schallerMichel vounatsosAlfred sandrock jrAllison parksMike henckeLynn kramerKenneth murrayHead of researchAlzheimer association international conferencePrnewswire eisai co ltdInvestor relations department